Q-omics provides the consensus-scored IRS2 profile across patient tissues and cancer cell-line models. IRS2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, IRS2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, IRS2 RNA expression shows 18,641 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, COAD, and THYM as cancer lineages where IRS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRS2 survival associations across molecular data types. IRS2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRS2 RNA expression–survival associations across cancer types. High IRS2 expression shows unfavorable associations in LGG, LUAD, UCEC and KIRP, but favorable associations in BRCA and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for IRS2 RNA expression.
This table summarizes IRS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IRS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRS2 shows lower tumor expression in BRCA, UCEC and BLCA and higher tumor expression in COAD, KICH and CHOL. The COAD box plot shows higher IRS2 RNA expression in tumor versus normal tissue (log2 FC = +1.285, t-test p < 0.001).
This table shows molecular features associated with IRS2 in patient tissues and cancer cell lines. In patient samples, IRS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IRS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
